Univariate and multivariate Cox regression analysis of variables investigated as potential predictors of sustained TFR at 12 mo
| Variable . | No. of patients (%) . | Patients in sustained TFR (%) . | Univariate analysis . | Multivariate analysis . | |||||
|---|---|---|---|---|---|---|---|---|---|
| β-coefficient . | HR (95% CI) . | P . | β-coefficient . | HR (95% CI) . | P . | Concordance index§ . | |||
| Halving time, d* | 102 (88.7) | 0.02 | 1.02 (1.01-1.03) | 2.26 × 10−8 | 0.03 | 1.03 (1.02-1.05) | 1.91 × 10−6 | 0.745 | |
| Transcript | |||||||||
| e14a2 | 51 (44.3) | 34 (66.7) | Ref | — | — | Ref | — | — | |
| e13a2 | 43 (37.4) | 17 (39.5) | 0.88 | 2.41 (1.30-4.44) | .005 | 0.91 | 2.49 (1.39-4.46) | .002 | |
| Both transcripts | 20 (17.4) | 11 (55.0) | 0.33 | 1.39 (0.62-3.11) | .43 | — | — | — | |
| Duration of TKI therapy, y* | 115 (100) | 0.56 | 1.75 (0.92-3.33) | .09 | 0.95 | 2.61 (1.05-6.09) | .03 | ||
| Time to MR4.5, y* | 115 (100) | −0.08 | 1.08 (0.99-1.18) | .08 | −0.07 | 0.93 (0.86-1.06) | .26 | ||
| 3-mo BCR-ABL1IS value* | 108 (94) | 0.03 | 1.03 (1.00-1.05) | .03 | −0.004 | 1.00 (0.96-1.03) | .80 | ||
| 3-mo BCR-ABL1 fold-reduction† | 102 (88.7) | 2.8 × 10−6 | 1.00 (1.00-1.01) | .008 | |||||
| Baseline BCR-ABL1IS value* | 111 (96.5) | −0.002 | 0.99 (0.99-1.00) | .35 | |||||
| Duration of MR4.5, y* | 115 (100) | 0.29 | 1.33 (0.75-2.38) | .33 | |||||
| Sex | |||||||||
| Male | 61 (53.0) | 32 (52.5) | Ref | — | — | ||||
| Female | 54 (47.0) | 31(57.4) | −0.16 | 0.85 (0.49-1.47) | .57 | ||||
| Age at TFR attempt* | 115 (100) | 0.26 | 1.30 (0.76-2.25) | .34 | |||||
| Sokal score | |||||||||
| Low | 49 (45.8) | 25 (51.0) | Ref | — | — | ||||
| Intermediate | 41 (38.3) | 22 (53.7) | −0.10 | 0.91 (0.50-1.65) | .74 | ||||
| High | 17 (15.9) | 9 (52.9) | <0.01 | 1.01 (0.45-2.24) | .99 | ||||
| ELTS score | |||||||||
| Low | 72 (67.9) | 38 (52.8) | Ref | — | — | ||||
| Intermediate | 26 (24.5) | 11 (42.3) | 0.28 | 1.33 (0.72-2.44) | .36 | ||||
| High | 8 (7.5) | 7 (87.5) | −1.57 | 0.20 (0.03-1.52) | .12 | ||||
| TKI ceased | |||||||||
| First-line imatinib | 60 (52.2) | 40 (66.7) | Ref | — | — | ||||
| First-line 2G-TKI | 17 (14.8) | 11 (64.7) | 0.26 | 1.29 (0.73-2.30) | .37 | ||||
| 2G-TKI for imatinib resistance | 8 (7.0) | 6 (75.0) | −0.09 | 0.92 (0.28-3.02) | .89 | ||||
| First-line TKI | |||||||||
| Imatinib | 89 (77.4) | 51 (57.3) | Ref | — | — | ||||
| 2G-TKI | 17 (14.8) | 12 (70.6) | −0.68 | 0.47 (0.20-1.27) | .14 | ||||
| EMR achieved | 98 (85.2) | 53 (54.1) | −0.38 | 0.68 (0.29-1.61) | .38 | ||||
| MMR by 12 mo | 86 (76.8) | 46 (53.5) | 0.09 | 1.10 (0.57-2.10) | .78 | ||||
| Variable . | No. of patients (%) . | Patients in sustained TFR (%) . | Univariate analysis . | Multivariate analysis . | |||||
|---|---|---|---|---|---|---|---|---|---|
| β-coefficient . | HR (95% CI) . | P . | β-coefficient . | HR (95% CI) . | P . | Concordance index§ . | |||
| Halving time, d* | 102 (88.7) | 0.02 | 1.02 (1.01-1.03) | 2.26 × 10−8 | 0.03 | 1.03 (1.02-1.05) | 1.91 × 10−6 | 0.745 | |
| Transcript | |||||||||
| e14a2 | 51 (44.3) | 34 (66.7) | Ref | — | — | Ref | — | — | |
| e13a2 | 43 (37.4) | 17 (39.5) | 0.88 | 2.41 (1.30-4.44) | .005 | 0.91 | 2.49 (1.39-4.46) | .002 | |
| Both transcripts | 20 (17.4) | 11 (55.0) | 0.33 | 1.39 (0.62-3.11) | .43 | — | — | — | |
| Duration of TKI therapy, y* | 115 (100) | 0.56 | 1.75 (0.92-3.33) | .09 | 0.95 | 2.61 (1.05-6.09) | .03 | ||
| Time to MR4.5, y* | 115 (100) | −0.08 | 1.08 (0.99-1.18) | .08 | −0.07 | 0.93 (0.86-1.06) | .26 | ||
| 3-mo BCR-ABL1IS value* | 108 (94) | 0.03 | 1.03 (1.00-1.05) | .03 | −0.004 | 1.00 (0.96-1.03) | .80 | ||
| 3-mo BCR-ABL1 fold-reduction† | 102 (88.7) | 2.8 × 10−6 | 1.00 (1.00-1.01) | .008 | |||||
| Baseline BCR-ABL1IS value* | 111 (96.5) | −0.002 | 0.99 (0.99-1.00) | .35 | |||||
| Duration of MR4.5, y* | 115 (100) | 0.29 | 1.33 (0.75-2.38) | .33 | |||||
| Sex | |||||||||
| Male | 61 (53.0) | 32 (52.5) | Ref | — | — | ||||
| Female | 54 (47.0) | 31(57.4) | −0.16 | 0.85 (0.49-1.47) | .57 | ||||
| Age at TFR attempt* | 115 (100) | 0.26 | 1.30 (0.76-2.25) | .34 | |||||
| Sokal score | |||||||||
| Low | 49 (45.8) | 25 (51.0) | Ref | — | — | ||||
| Intermediate | 41 (38.3) | 22 (53.7) | −0.10 | 0.91 (0.50-1.65) | .74 | ||||
| High | 17 (15.9) | 9 (52.9) | <0.01 | 1.01 (0.45-2.24) | .99 | ||||
| ELTS score | |||||||||
| Low | 72 (67.9) | 38 (52.8) | Ref | — | — | ||||
| Intermediate | 26 (24.5) | 11 (42.3) | 0.28 | 1.33 (0.72-2.44) | .36 | ||||
| High | 8 (7.5) | 7 (87.5) | −1.57 | 0.20 (0.03-1.52) | .12 | ||||
| TKI ceased | |||||||||
| First-line imatinib | 60 (52.2) | 40 (66.7) | Ref | — | — | ||||
| First-line 2G-TKI | 17 (14.8) | 11 (64.7) | 0.26 | 1.29 (0.73-2.30) | .37 | ||||
| 2G-TKI for imatinib resistance | 8 (7.0) | 6 (75.0) | −0.09 | 0.92 (0.28-3.02) | .89 | ||||
| First-line TKI | |||||||||
| Imatinib | 89 (77.4) | 51 (57.3) | Ref | — | — | ||||
| 2G-TKI | 17 (14.8) | 12 (70.6) | −0.68 | 0.47 (0.20-1.27) | .14 | ||||
| EMR achieved | 98 (85.2) | 53 (54.1) | −0.38 | 0.68 (0.29-1.61) | .38 | ||||
| MMR by 12 mo | 86 (76.8) | 46 (53.5) | 0.09 | 1.10 (0.57-2.10) | .78 | ||||
CI, confidence interval; HR, hazard ratio; Ref, reference variable.
Continuous variables.
Harrell’s Concordance Index is a measure of the goodness of fit of the prediction model.58
3-month fold-reduction is assessed in a separate multivariate analysis model to avoid collinearity with the 3-mo halving time (supplemental Table 2).